# A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

> **NCT01551056** · PHASE3 · COMPLETED · sponsor: **Aciex Therapeutics, Inc.** · enrollment: 91 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** AC-170 0.24%
- **DRUG:** AC-170 0%

## Key facts

- **NCT ID:** NCT01551056
- **Lead sponsor:** Aciex Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-03
- **Primary completion:** 2012-06
- **Final completion:** 2012-06
- **Target enrollment:** 91 (ACTUAL)
- **Last updated:** 2017-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01551056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01551056, "A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01551056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*